Login to Your Account



Amarin Raises $91.2M in Public Offering for AMR101 Sales Prep

By Trista Morrison


Friday, January 7, 2011
With Phase III trials for triglyceride-lowering drug AMR101 (ethyl icosapentate) nearly complete, Amarin Corp. plc raised $91.2 million in a public offering of American Depository Shares.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription